Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.31), $0.06 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1 million versus the consensus estimate of $2.87 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.